Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
325.1 GBX | +0.12% | +0.65% | +1.07% |
May. 21 | Bernstein becomes more optimistic for consumer goods - Henkel upgraded | DP |
May. 17 | UK's FTSE 100 Closes Lower Amid Inflation Focus | MT |
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The company returns high margins, thereby supporting business profitability.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- Considering the small differences between the analysts' various estimates, the group's business visibility is good.
Weaknesses
- With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
- The company is in debt and has limited leeway for investment
- The company's enterprise value to sales, at 3.28 times its current sales, is high.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.07% | 37.78B | B | ||
+40.73% | 739B | C+ | ||
+32.83% | 598B | B | ||
-6.30% | 353B | C+ | ||
+15.15% | 318B | B- | ||
+4.05% | 285B | C+ | ||
+15.00% | 240B | B+ | ||
+9.78% | 210B | B- | ||
-5.52% | 206B | A+ | ||
+6.17% | 164B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- HLN Stock
- Ratings Haleon plc